Invasive Lobular Carcinoma Research Takes Center Stage at 7th International Symposium

Invasive lobular carcinoma, the second most common form of breast cancer, has long lived in the shadow of its more famous counterpart, invasive ductal carcinoma. Now a growing international research community is working to change that. The seventh biannual International Invasive Lobular Carcinoma Symposium brought together clinicians, pathologists, and basic scientists to share the latest findings on this distinct disease, and a curated collection of oral and poster presentations from the meeting has been published as a supplement in the journal Breast Cancer Research and Treatment.

The publication of selected abstracts marks an important milestone for a field that has historically struggled for recognition. Lobular breast cancers account for roughly 10 to 15 percent of all invasive breast cancers, yet they behave in ways that standard diagnostic and treatment frameworks often fail to capture. Unlike ductal carcinomas, lobular tumors typically lack the cell adhesion molecule E-cadherin, which allows cancer cells to grow in single-file patterns rather than forming discrete masses. This growth pattern makes lobular cancers notoriously difficult to detect on mammography and to measure accurately on imaging, meaning many patients are diagnosed at later stages than women with ductal tumors.

The symposium itself has grown from a small gathering of specialists into a biannual international event that draws researchers from across oncology, pathology, radiology, and computational biology. The abstract review committee for the 2026 meeting, which held full responsibility for selecting the presentations featured in the supplement, evaluated submissions spanning the full spectrum of lobular carcinoma research, from molecular mechanisms of metastasis to novel imaging strategies and clinical trial design tailored specifically to lobular biology.

One of the central themes running through lobular carcinoma research is the disease’s distinctive metastatic behavior. While ductal breast cancers most often spread to bone, lung, liver, and brain, lobular carcinomas show a striking predilection for unusual metastatic sites, including the gastrointestinal tract, gynecologic organs, and the leptomeninges. These patterns have historically led to delayed or missed diagnoses of metastatic disease, and several presentations at the symposium addressed improved surveillance strategies and the molecular drivers behind this unusual organ tropism.

Imaging challenges also featured prominently in the meeting program. Because lobular tumors infiltrate tissue diffusely rather than forming well-defined lumps, standard mammography frequently underestimates tumor size, and magnetic resonance imaging has emerged as a critical tool for surgical planning. Research presented at the symposium explored how advanced imaging modalities can improve the accuracy of tumor measurement, reduce the need for repeated surgeries, and help clinicians monitor response to neoadjuvant therapy in a disease where conventional response criteria often fall short.

The publication of the abstract collection was sponsored by the University of California San Francisco and funded through a National Cancer Institute grant, reflecting growing institutional support for lobular-specific research. The National Institutes of Health has historically allocated research funding based on disease prevalence and mortality, and advocates for lobular carcinoma patients have argued that the disease’s distinct biology warrants dedicated research investment rather than being folded into general breast cancer programs. The R13 conference grant mechanism that supported the symposium publication is specifically designed to foster scientific meetings that advance research in defined areas.

Genomic research has been a particular driver of the field’s recent momentum. Lobular carcinomas frequently harbor mutations in the CDH1 gene, which encodes E-cadherin, and they also show characteristic alterations in the PI3K signaling pathway and in the transcription factor FOXA1. These molecular features open potential avenues for targeted therapies, and clinical trials of PI3K inhibitors and endocrine therapy combinations in lobular-specific cohorts have been a recurring focus of recent symposia. The abstracts published from the seventh meeting reflect continued interest in translating these genomic insights into treatment strategies that account for the disease’s unique biology.

Another important dimension of the symposium is its role in building a coordinated international research community. Because lobular carcinoma is less common than ductal disease, individual institutions often lack sufficient patient numbers to run robust studies. Collaborative networks formed through the symposium have enabled multi-institutional clinical trials, shared tissue banking efforts, and harmonized data collection, all of which are essential for advancing a disease that requires larger cohorts to generate statistically meaningful results. The supplement’s collection of abstracts serves as a snapshot of this collaborative enterprise, documenting work from laboratories and clinics around the world.

Patient advocacy has also been woven into the symposium’s evolution. Lobular patients often describe a diagnostic odyssey marked by negative mammograms, vague imaging findings, and a lack of disease-specific information. Advocacy organizations have pushed for greater awareness among clinicians and for research that addresses the questions most relevant to patients, including how to monitor for recurrence, how to manage the anxiety of a disease that is hard to image, and how to counsel women with hereditary CDH1 mutations about their cancer risks. The growing visibility of the symposium reflects this advocacy in action.

As the field moves forward, researchers hope that the momentum generated by meetings like the seventh biannual symposium will translate into meaningful clinical improvements: earlier and more accurate detection, better prediction of metastatic risk, and therapies designed specifically for the molecular vulnerabilities of lobular cancer cells. The published abstracts offer a window into that effort, capturing the questions, methods, and early findings that will shape the next generation of lobular carcinoma research. For a disease that has long been understudied relative to its clinical impact, the sustained growth of this international gathering signals that invasive lobular carcinoma is finally getting the focused scientific attention that patients have long called for.

Subject of Research: Selected research abstracts on invasive lobular carcinoma biology, detection, and treatment presented at the 7th biannual international symposium

Article Title: Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations

Article References: Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations. (2026). Breast Cancer Research and Treatment, 219(S1), Article 17. https://doi.org/10.1007/s10549-026-08047-8

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08047-8

Keywords: invasive lobular carcinoma, breast cancer, symposium abstracts, E-cadherin, CDH1, metastasis, breast imaging, Breast Cancer Research and Treatment, National Cancer Institute, lobular breast cancer research, clinical trials, molecular biology